The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis
Abstract
In August 1997, AmBisome (liposomal amphotericin B, Nexstar, San Dimas, CA) was the first drug approved for the treatment of visceral leishmaniasis by the U.S. Food and Drug Administration. The growing recognition of emerging and reemerging infections warrants that safe and effective agents to treat such infections be readily available in the United States. The following discussion of the data submitted in support of the New Drug Application for AmBisome for the treatment of visceral leishmaniasis shows the breadth of data from clinical trials that can be appropriate to support approval for drugs to treat tropical diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years
Berman, J. D. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.684 · Cited by 806
Clinical Spectrum of Leishmaniasis
Pearson, R. D., & Sousa, A. D. Q. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.1.1 · Cited by 543
Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial
(1994) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068903 · Cited by 195
Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)
Davidson, R. N., di Martino, L., Gradoni, L., Giacchino, R., Gaeta, G. B., Pempinello, R., Scotti, S., Cascio, A., Castagnola, E., Maisto, A., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.6.938 · Cited by 163
Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions
Seaman, J., Boer, C., Wilkinson, R. J., de Jong, J., Wilde, E., Sondorp, E., & Davidson, R. N. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.1.188 · Cited by 109
Russo, R., Nigro, L., Minniti, S., Montineri, A., Gradoni, L., Caldeira, L., & Davidson, R. N. (1996) · Journal of Infection · doi:10.1016/s0163-4453(96)91343-2 · Cited by 94
Torre‐Cisneros, J., Villanueva, J., Kindelán, J. M., Jurado, R., & Sanchez-Guijo, F. M. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.625 · Cited by 69
Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B
Gokhale, P. C., Kshirsagar, N. A., Khan, M. U., Pandya, S. K., Meisheri, Y. V., Thakur, C. P., & Choudhary, C. B. (1994) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(94)90309-3 · Cited by 20
Cited by
Yusuf, A., Almotairy, A. R. Z., Henidi, H., Alshehri, O. Y., & Aldughaim, M. S. (2023) · Polymers · doi:10.3390/polym15071596 · Cited by 914
Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs
Croft, S. L., & Coombs, G. H. (2003) · Trends in Parasitology · doi:10.1016/j.pt.2003.09.008 · Cited by 891
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Metadata
- Authors
- Meyerhoff, A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-01
- Volume
- 28
- Issue
- 1
- Pages
- 42-48
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2094444526
- Cited by
- 295
- References
- 8
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis. https://app.cochat.ai/papers/10.1086/515085
- The paper
- Meyerhoff, A. (1999). U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral Leishmaniasis. Clinical Infectious Diseases. https://doi.org/10.1086/515085
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
